Notice of Interim Results
Updated : 07:06
Vectura Group plc
Notice of Interim Results
Chippenham, UK, 18 July 2018: Vectura Group plc (LSE: VEC) ("Vectura" or the "Group"), an industry-leading inhaled product formulation, device design and development business, plans to announce its Interim Results for the 6 months ended 30 June 2018 on Tuesday 11 September 2018.
James Ward-Lilley, Chief Executive Officer, will host a briefing for analysts at 9.30am on the morning of the results at the offices of Numis Securities Ltd., 10 Paternoster Square, London, EC4M 7LT.
A live webcast of the meeting, with the presentation slides, will be available on Vectura's website: https://www.vectura.com/investors/presentations-and-webcasts.
- ENDS -
For more information, please contact:
Vectura Group plc | +44 (0)7471 352 720 | |
David Ginivan - VP Corporate Communications Julia Wilson - Director Investor Relations | +44 (0)7818 430 877 | |
|
| |
Consilium Strategic Communications | +44 (0)20 3709 5700 | |
Mary-Jane Elliott / Jessica Hodgson / David Daley | ||
| ||
About Vectura
Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.
Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at www.vectura.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.